Sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces serum urate levels and risk for adverse events in patients with gout, according to results of a post hoc analysis presented at the 55th Annual Meeting of the European Association for the Study of Diabetes, held September 16 to 20, 2019, in Barcelona, Spain.
The CANagliflozin cardioVascular Assessment Study (CANVAS) Program (ClinicalTrials.gov Identifier: NCT01032629) included 10,142 patients with type 2 diabetes randomly assigned to receive either canagliflozin or placebo.
Using hazard ratios (HRs) and 95% CIs, the current study compared the effects of canagliflozin vs placebo in patients who experienced an adverse event related to gout or those who began gout treatment in the CANVAS program.
Mean baseline serum urate levels were 5.85±1.59 mg/dL in the canagliflozin group and 5.88±1.63 mg/dL in the placebo group. Results showed that average serum urate levels were 0.39 mg/dL (95% CI, -0.43 to -0.36 mg/dL) lower among patients who received canagliflozin compared with those who received placebo during follow-up.
Researchers found that occurrence of gout (n=70; HR, 0.58; 95% CI, 0.36-0.94) or the need for commencement of a drug for gout (n=147; HR, 0.52; 95% CI, 0.38-0.72) was reduced in patients who received canagliflozin compared with those who received placebo (HR, 0.52; 95% CI, 0.38-0.69).
Overall, serum urate levels and risk for adverse events in gout were reduced with canagliflozin treatment in patients with type 2 diabetes.
Disclosure: This study was supported by Janssen Global Services, LLC. Please see the original reference for a full list of authors’ disclosures.
Mahaffey KW, Li J, Badve SV, et al. The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS program. Presented at: European Association for the Study of Diabetes 55th Annual Meeting; September 16-20, 2019; Barcelona, Spain. Abstract 711.
This article originally appeared on Endocrinology Advisor